Internship

2025 Intern

Clinical Supply Planning

Posted on 11/12/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Cambridge, MA, USA

Internship requires on-site presence in Cambridge, MA from January 21 to June 15, 2025.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
PowerPoint/Keynote/Slides
Requirements
  • Current student enrolled in a Bachelors or Masters program in Chemical Engineering, Biochemical Engineering, Bioengineering, Biomolecular Engineering, Chemistry, Biochemistry, Biomedical Engineering, Biophysics, Biostatistics, Biotechnology, Mathematics, Molecular Biology, Pharmaceutical Science, Statistics, or a related field
  • Creative, capable problem-solver
  • Ideal candidate will have some level of proficiency with Excel, Outlook, Word, MS Project, PowerPoint, Smart Sheets
  • High level of attention to detail
Responsibilities
  • Liaise with Clinical Supply Project Managers and Planners to facilitate logistics as required to support the movement of unlabeled drug product
  • Collaborates with CMC, clinical operations, and project management to ensure timing of clinical trial drug needs are met
  • Manage and monitor expiration dating for coordination of expiry extension with CMC
  • Monitor inventory and distribution activities and update forecasting actuals on regular basis
  • Utilize internal forecasting solution to create demand planning for various studies
  • Participate in user acceptance testing (UAT) of forecasting solution and other clinical supply systems as required
  • Contribute to management of demand planning cycle within Clinical Development Organization
  • Manage Temperature Excursions as required to ensure no dosing interruptions
  • Monitor and assist with presentation of KPIs and metrics for demand/supply planning for Clinical Supply Organization
  • Ensures work is done in compliance to relevant SOPs

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to harness the body's own cellular machinery for healing. The company's goal is to improve patient outcomes by transforming the way medicines are discovered, developed, and manufactured, making mRNA a central element in future medical treatments.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's mRNA cancer vaccine shows a 44% reduction in melanoma recurrence risk.
  • Collaboration with Vertex for cystic fibrosis mRNA therapies is progressing well.
  • AI optimization of mRNA design could reduce development time and costs.

What critics are saying

  • Potential removal from Nasdaq 100 could affect investor perception and stock liquidity.
  • Hong Kong's vaccine reticence may indicate broader market acceptance challenges.
  • Expansion in China may face geopolitical risks and regulatory hurdles.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has developed one of the earliest and most effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious diseases, immuno-oncology, and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE